- Wednesday, December 4
- 12:50 PM - 1:50 PM
- Grand Ballroom West, Level 3
Soon diabetic kidney disease is expected to surpass all other diabetes-related complications in morbidity and mortality. Data suggest that the excess risk related to all-cause and cardiovascular mortality is concentrated among the those with T2DM and kidney disease. SGLT2 inhibitors have shown particular cardiovascular and renoprotective benefits. In this session, faculty will explain current data on the renoprotective properties of SGLT2 inhibitors and review guideline recommendations for using them in patients with type 2 diabetes and kidney disease. The practical cases throughout the lecture will train you to develop treatment plans for your patients with those comorbid diseases and enhance individualized care in your practice.
Explain current data surrounding the renoprotective properties of SGLT2 inhibitors
Review current guideline recommendations for using SGLT2 inhibitors in patients with T2DM and kidney disease
Develop individualized treatment plans for patients with T2DM and kidney disease